Meeting
2023 ASCO Annual Meeting
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
Authors
Susan Halabi
Duke University Medical Center, Durham, NC
Susan Halabi , Siyuan S Guo , Akash Roy , Larysa Rydzewska , Peter Godolphin , Maha H. A. Hussain , Catherine Tangen , Ian Thompson Jr., Wanling Xie , Michael Anthony Carducci , Matthew Raymond Smith , Michael J. Morris , Gwenaelle Gravis , David P. Dearnaley , Paul Verhagen , Takayuki Goto , Nicholas D. James , Mahesh Parmar , Marc E. Buyse , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT00309985; NCT00268476; NCT00104715; NCT00079001; NCT00002651; NCT00685646
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5073)
DOI
10.1200/JCO.2023.41.16_suppl.5073
Abstract #
5073
Poster Bd #
167
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
First Author: Abhishek Tripathi
Poster
2017 Genitourinary Cancers Symposium
Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel.
First Author: Gwenaelle Gravis
Poster
2023 ASCO Annual Meeting
Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
First Author: Neal D. Shore
Poster
2023 ASCO Annual Meeting
Development and independent validation of a predictive gene expression signature based on RB1, PTEN, and TP53 in patients with metastatic hormone-sensitive metastatic prostate cancer (mHSPC).
First Author: Oscar Reig Torras